Stocktoria
Precipio, Inc. PRPO
Precipio, Inc. (PRPO) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $53.5M at a -0.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.72 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.107 |
| Retained earnings / assets | -4.823 |
| EBIT / assets | -0.056 |
| Equity / liabilities | 2.155 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PRPO | Precipio, Inc. | 7/9 | -13.13 | — | +28% |
| RPID | RAPID MICRO BIOSYSTEMS, INC. | 2/9 | — | — | +19.7% |
| EYPT | EyePoint, Inc. | 1/9 | -3.58 | — | -27.5% |
| BNGO | Bionano Genomics, Inc. | 3/9 | — | — | -7.4% |
| HBIO | HARVARD BIOSCIENCE INC | 4/9 | -10.45 | — | -8.1% |
| SEER | Seer, Inc. | 3/9 | 4.62 | — | +17% |
| ASTC | ASTROTECH Corp | 2/9 | — | — | — |
About Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
FAQ
Is PRPO financially healthy?
Precipio, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PRPO pay a dividend?
No, Precipio, Inc. does not currently pay a dividend.
How profitable is PRPO?
In FY2025, Precipio, Inc. had a net margin of -0.7% and a return on equity of -2.5%.
Is PRPO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Precipio, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.